John T. Mondick, Ph.D.

Group Leader, Principal Scientist II

John has 5 years of experience in the pharmaceutical industry and academia applying modeling and simulation to problems in clinical pharmacology. John’s interests include the application of modeling and simulation in pediatric pharmacology and the development of mechanistic models to optimize decision making in drug development.

Recent publications by this scientist

A latent variable disease progression model for Duchenne muscular dystrophy

October 9, 2018

Hajjar J. Poster presented at 2018 American Conference on Pharmacometrics (ACoP9). San Diego, CA. 9 Oct 2018. Abstract #T-011.

Download PDF

Population pharmacokinetic – pharmacodynamic analysis to characterize the effect of empagliflozin on renal glucose threshold in patients with type 1 diabetes mellitus

May 31, 2018

Mondick J, Riggs M, Kaspers S, Soleymanlou N, Marquard J, Nock V. J Clin Pharmacol. 58 (5): 640-649; May 2018

Download PDF

Animal-to-human dose translation of obiltoxaximab for treatment of inhalational anthrax under the US FDA animal rule.

December 1, 2016

Nagy CF, Mondick J, Serbina N, Casey LS, Carpenter SE, French J, Guttendorf R.  Clinical And Translational Science, 2016 Dec; 10: 12–19.

Download PDF